ADVA
26.4.2022 09:02:06 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that Schleswig-Holstein Netz, one of northern Germany’s largest power grid operators, has successfully completed a field trial of quantum-secured data transport using the ADVA FSP 3000 platform with ConnectGuard™ Layer 1 encryption technology. For the first time with a full commercial solution, a future-proof key exchange based on quantum key distribution (QKD) was used to encrypt data across overhead fiber cables. Until now, ensuring QKD performance in the harsh outdoor conditions of aerial fiber was thought to be a major barrier. The trial shows how mission-critical utility networks can now counter the urgent threat of attacks from quantum computers. Technology from ADVA’s partner, the quantum cryptography company ID Quantique, also played a significant role generating QKD keys.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220425005727/en/
“The emergence of large quantum computers will jeopardize mission-critical networks like never before. That’s why we’re taking action now and trialing technology to safeguard power infrastructure for the long term. The success of our PoC with ADVA’s secure solution is a key breakthrough for protecting utility networks with QKD,” said Benjamin Merkt, CTO of Schleswig-Holstein Netz. “We’ve shown that grids like ours that use aerial fiber stretching across hundreds of kilometers can be protected against quantum-enabled hacking, even in adverse climactic conditions. It’s a major step towards guaranteeing the integrity and security of critical data in transit both today and in the post-quantum world.”
QKD offers a way to secure sensitive data transport against all forms of cyberattack, including from quantum computers that could render traditional public key cryptography useless. Distributing encryption keys in a quantum state ensures that any attempt to intercept traffic disturbs photons, introducing coding errors and alerting operators. But implementing the technology in power infrastructure is challenging as most utility communication networks are integrated with long-distance high-voltage overhead lines. As QKD performance can be easily affected by environmental factors, stability was a key criterion in Schleswig-Holstein Netz’s trial, but the configuration proved to be stable and suitable for aerial fiber. The success of ADVA’s solution shows a way forward for quantum-secure utility networks.
“This PoC proves that QKD-based encryption is achievable in network architectures like this. Even with fiber optics integrated with 110kV overhead lines and unprotected from wind, solar radiation and thunderstorms, our solution was successful,” commented Helmut Griesser, director of advanced technology at ADVA. “Working closely with Schleswig-Holstein Netz and our partner ID Quantique, we’ve been able to demonstrate that QKD has a major role in safeguarding utilities. We’ve shown that our FSP 3000 ConnectGuard™ encryption has the power to protect our most sensitive and vital assets from cybercriminals even in the age of quantum computers.”
The PoC was performed as part of the OPENQKD project , which is supported by the European Union’s Horizon 2020 research and innovation program. The project creates several testbeds and demonstrates numerous use cases, laying the foundations of a pan-European quantum network.
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
About ID Quantique
Founded in 2001 as a spin-off of the Group of Applied Physics of the University of Geneva, ID Quantique is the world leader in quantum-safe crypto solutions, designed to protect data for the future. The company provides quantum-safe network encryption, secure quantum key generation and Quantum Key Distribution solutions and services to the financial industry, enterprises and government organizations globally. IDQ’s quantum random number generator has been validated according to global standards and independent agencies, and is the reference in highly regulated and mission critical industries – such as security, encryption, critical infrastructure and IoT – where trust is paramount. For more information, please visit www.idquantique.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220425005727/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
